← Back to Search

Tyrosine Kinase Inhibitor

Deferred nephrectomy for Kidney Cancer (SURTIME Trial)

Phase 3
Waitlist Available
Research Sponsored by European Organisation for Research and Treatment of Cancer - EORTC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

SURTIME Trial Summary

RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib malate before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving sunitinib malate after surgery may kill any tumor cells that remain after surgery. It is not yet known whether undergoing immediate surgery or surgery after sunitinib malate is more effective in treating patients with metastatic kidney cancer. PURPOSE: This randomized phase III trial is studying immediate surgery to see how well it works compared with surgery after sunitinib malate in treating patients with metastatic kidney cancer.

Eligible Conditions
  • Kidney Cancer

SURTIME Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall progression-free survival
Secondary outcome measures
Effect of nephrectomy on early progression in both arms
Morbidity
Overall response to treatment in the deferred nephrectomy arm including the proportion of patients who become unresectable
+1 more

SURTIME Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Deferred nephrectomyExperimental Treatment4 Interventions
Sunitinib (3 cycles) followed by surgery followed by Sunitinib
Group II: Immediate nephrectomyActive Control4 Interventions
Surgery followed by Sunitinib
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
gene expression analysis
2006
Completed Phase 2
~2030

Find a Location

Who is running the clinical trial?

Institute of Cancer Research, United KingdomOTHER
157 Previous Clinical Trials
130,212 Total Patients Enrolled
Wales Cancer Trials UnitOTHER
8 Previous Clinical Trials
2,375 Total Patients Enrolled
Canadian Urologic Oncology GroupOTHER
7 Previous Clinical Trials
818 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer
2010. "Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01099423.
All > Kidney Cancer
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top